CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc.（CTMX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · CTMX · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
9
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
CytomX Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
CTMX 季度内部人买卖趋势
CTMX 内幕交易卖出 · CTMX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · CTMX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
CTMX 高管卖出股份 · CTMX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Mar 17, 2026 | Chu Yu-Waye Chief Medical Officer | Sale | 21,279 | $137K | Form 4 |
| Mar 17, 2026 | McCarthy Sean A. CEO · Director | Sale | 118,969 | $764K | Form 4 |
| Mar 17, 2026 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 31,492 | $202K | Form 4 |
| Mar 17, 2026 | Ogden Christopher CFO | Sale | 19,323 | $124K | Form 4 |
| Feb 2, 2026 | Lester Rachael Chief Business Officer | Award | 20,000 | — | Form 4 |
| Feb 2, 2026 | Chu Yu-Waye Chief Medical Officer | Award | 75,000 | — | Form 4 |
| Feb 2, 2026 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 60,000 | — | Form 4 |
| Feb 2, 2026 | Ogden Christopher CFO | Award | 90,000 | — | Form 4 |
| Feb 2, 2026 | McCarthy Sean A. CEO · Director | Award | 210,000 | — | Form 4 |
| Jun 13, 2025 | Ogden Christopher CFO | Option | 37,500 | — | Form 4 |
| Jun 16, 2025 | Ogden Christopher CFO | Sale | 10,614 | $29K | Form 4 |
| Jun 13, 2025 | Ogden Christopher CFO | Sale | 1,641 | $5K | Form 4 |
| Jun 13, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Option | 37,500 | — | Form 4 |
| Jun 16, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 13,884 | $37K | Form 4 |
| Jun 13, 2025 | McCarthy Sean A. CEO · Director | Option | 150,000 | — | Form 4 |
| Jun 16, 2025 | McCarthy Sean A. CEO · Director | Sale | 55,511 | $149K | Form 4 |
| Mar 18, 2025 | McCarthy Sean A. CEO · Director | Sale | 37,656 | $23K | Form 4 |
| Mar 18, 2025 | Ogden Christopher CFO | Sale | 8,551 | $5K | Form 4 |
| Mar 18, 2025 | Chu Yu-Waye Chief Medical Officer | Sale | 4,025 | $2K | Form 4 |
| Mar 18, 2025 | ROWLAND LLOYD A General Counsel | Sale | 10,203 | $6K | Form 4 |
| Mar 18, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Sale | 19,512 | $12K | Form 4 |
| Feb 4, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 57,500 | — | Form 4 |
| Feb 4, 2025 | BELVIN MARCIA SVP, Chief Scientific Officer | Award | 30,000 | — | Form 4 |
| Feb 4, 2025 | Chu Yu-Waye Chief Medical Officer | Award | 57,500 | — | Form 4 |
| Feb 4, 2025 | Chu Yu-Waye Chief Medical Officer | Award | 56,000 | — | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 CTMX 内幕交易
CTMX 内幕交易
CytomX Therapeutics, Inc.（CTMX）内幕交易数据来源于公司内部人（包括Ogden Christopher (CFO), McCarthy Sean A. (CEO · Director), BELVIN MARCIA (SVP, Chief Scientific Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。CTMX内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看CytomX Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
CTMX 内幕交易 · 5个问题CytomX Therapeutics, Inc.（CTMX）的内部人包括高管和董事，如Ogden Christopher (CFO), McCarthy Sean A. (CEO · Director), BELVIN MARCIA (SVP, Chief Scientific Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026